ReviewJournal of clinical medicine2021
Thrombotic Complications in Patients with Immune-Mediated Hemolysis.
Review in Journal of clinical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 32 citations in OpenAlex.
- Hematologic complications and design challenges in cardiovascular devices.Communications engineering · 2026Review
- Occurrence of Cold Agglutinin Disease among Patients with Autoimmune Hemolytic Anemia: A Hungarian Single-Center Experience.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2026Article
- Cerebral venous sinus thrombosis with cold agglutinin disease in summer: illustrative case.Journal of neurosurgery. Case lessons · 2025Article
- Thrombosis and Anemia in Pediatric Inflammatory Bowel Disease: Pathophysiology, Clinical Impact and Future Directions.International journal of molecular sciences · 2025Review
- Prediction of thrombotic events in patients with autoimmune hemolytic anemia: a multicenter retrospective observational study.Journal of thrombosis and thrombolysis · 2025Observational
- Article
- Thalassemias and Sickle Cell Diseases in Pregnancy: SITE Good Practice.Journal of clinical medicine · 2025Article
- Article
- Extremely Rare Case of Successful Treatment of Foot Ulcer Associated with Evans' Syndrome and Buerger's Disease.Medicina (Kaunas, Lithuania) · 2024Article
- Cutting-Edge Techniques and Drugs for the Treatment of Pulmonary Embolism: Current Knowledge and Future Perspectives.Journal of clinical medicine · 2024Review
- Thromboembolism Early After Glucocorticoid Administration in Patients with Autoimmune Hemolytic Anemia.Clinical hematology international · 2023Article
- Infrequent Thrombotic Complications in Japanese Patients with Warm Autoimmune Hemolytic Anemia.Internal medicine (Tokyo, Japan) · 2023Article
- Severe autoimmune hemolytic anemia; epidemiology, clinical management, outcomes and knowledge gaps.Frontiers in immunology · 2023Review
- Intravascular hemolysis and multitreatment predict thrombosis in patients with autoimmune hemolytic anemia.Journal of thrombosis and haemostasis : JTH · 2022Article
- Iron deficiency anemia and thrombosis risk in children-revisiting an old hypothesis.Frontiers in pediatrics · 2022Review
- Concomitant autoimmune hemolytic anemia and pulmonary embolism associated with mild COVID-19: A case report.Clinical case reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autoimmune hemolytic anemias are rare and heterogeneous disorders characterized by hemolysis, which is a well-recognized risk factor for thrombosis. The most common immune-mediated anemias are represented by autoimmune hemolytic anemia and paroxysmal nocturnal hemoglobinuria, both associated with a high rate of thrombosis. Multiple pathophysiological mechanisms for thrombosis have been proposed, involving hemolysis itself and additional effects of the immune system. Despite the increasing awareness of the thrombotic risk in these conditions, evidence-based guidance on prevention and management of thrombotic events is lacking. We herein report available evidence on epidemiological data on thrombosis and thrombophilia in immune-mediated hemolysis, together with possible underlying pathophysiological mechanisms. In addition, we summarize current recommendations for treatment of thrombosis in immune-mediated hemolysis. In particular, we address the issue of thrombotic complications treatment and prophylaxis by proposing a therapeutic algorithm, focusing on specific situations such as splenectomy and pregnancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.